-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15

Benzinga·11/02/2026 18:03:05
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.